HC Wainwright Has Bullish Outlook for MIRM FY2024 Earnings

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) – Stock analysts at HC Wainwright upped their FY2024 earnings per share estimates for shares of Mirum Pharmaceuticals in a research report issued to clients and investors on Wednesday, November 13th. HC Wainwright analyst E. Arce now anticipates that the company will earn ($0.38) per share for the year, up from their prior estimate of ($0.81). HC Wainwright currently has a “Buy” rating and a $66.00 target price on the stock. The consensus estimate for Mirum Pharmaceuticals’ current full-year earnings is ($1.81) per share. HC Wainwright also issued estimates for Mirum Pharmaceuticals’ Q4 2024 earnings at ($0.27) EPS, Q1 2025 earnings at ($0.09) EPS, Q2 2025 earnings at $0.12 EPS, FY2025 earnings at $1.00 EPS, FY2026 earnings at $5.48 EPS, FY2027 earnings at $6.98 EPS and FY2028 earnings at $10.38 EPS.

Several other equities research analysts have also issued reports on the company. Citigroup raised their price objective on Mirum Pharmaceuticals from $65.00 to $68.00 and gave the company a “buy” rating in a research note on Wednesday. Cantor Fitzgerald lifted their price objective on shares of Mirum Pharmaceuticals from $50.00 to $60.00 and gave the stock an “overweight” rating in a research note on Thursday, August 8th. Leerink Partners increased their target price on shares of Mirum Pharmaceuticals from $47.00 to $49.00 and gave the company an “outperform” rating in a research note on Thursday, October 17th. Evercore ISI lifted their price target on shares of Mirum Pharmaceuticals from $62.00 to $66.00 and gave the stock an “outperform” rating in a research note on Thursday, August 8th. Finally, Robert W. Baird increased their price objective on shares of Mirum Pharmaceuticals from $44.00 to $50.00 and gave the stock an “outperform” rating in a research report on Wednesday. Ten analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $57.73.

Mirum Pharmaceuticals Trading Up 5.3 %

MIRM opened at $46.26 on Friday. The stock has a 50-day moving average of $39.96 and a 200 day moving average of $35.79. The company has a current ratio of 3.34, a quick ratio of 3.09 and a debt-to-equity ratio of 1.33. Mirum Pharmaceuticals has a 12 month low of $23.14 and a 12 month high of $48.89. The firm has a market cap of $2.22 billion, a P/E ratio of -22.90 and a beta of 1.16.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.30) EPS for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.15. The business had revenue of $90.38 million during the quarter, compared to analysts’ expectations of $81.99 million. Mirum Pharmaceuticals had a negative net margin of 31.69% and a negative return on equity of 41.22%. The business’s revenue was up 89.4% on a year-over-year basis. During the same period last year, the company posted ($0.57) EPS.

Institutional Trading of Mirum Pharmaceuticals

Large investors have recently modified their holdings of the company. Janus Henderson Group PLC lifted its holdings in shares of Mirum Pharmaceuticals by 34.2% in the 1st quarter. Janus Henderson Group PLC now owns 2,767,210 shares of the company’s stock worth $69,470,000 after buying an additional 704,659 shares during the period. Price T Rowe Associates Inc. MD raised its stake in Mirum Pharmaceuticals by 37.2% in the first quarter. Price T Rowe Associates Inc. MD now owns 1,597,506 shares of the company’s stock worth $40,131,000 after buying an additional 432,824 shares in the last quarter. Clearbridge Investments LLC boosted its position in Mirum Pharmaceuticals by 165.5% during the 2nd quarter. Clearbridge Investments LLC now owns 699,933 shares of the company’s stock valued at $23,931,000 after acquiring an additional 436,349 shares in the last quarter. William Blair Investment Management LLC increased its holdings in shares of Mirum Pharmaceuticals by 8.1% in the 2nd quarter. William Blair Investment Management LLC now owns 677,939 shares of the company’s stock valued at $23,179,000 after acquiring an additional 50,667 shares during the period. Finally, Candriam S.C.A. bought a new position in shares of Mirum Pharmaceuticals in the 2nd quarter worth $17,384,000.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.